Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population

Cruyssen, Bert Vander; Durez, Patrick; Westhovens, Rene; De Clerck, Luc; Peretz, Ann; Verbruggen, Leon; Vastesaeger, Nathan; Noel, Wim; De Keyser, Filip

Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population

Cruyssen, Bert Vander

;

Durez, Patrick

;

Westhovens, Rene

;

De Clerck, Luc

;

De Keyser, Filip

;et.al.

(2008) Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology — Location: Liverpool (England) (22.April.2007)

Files

No attached file found for this publication.

Details

Authors

Cruyssen, Bert Vander
Author
Durez, PatrickUCLouvain
Author
Westhovens, ReneUCLouvain
Author
De Clerck, Luc
Author
De Keyser, Filip
Author

Affiliations

Citations

APA
Chicago
FWB

Cruyssen, B. V., Durez, P., Westhovens, R., De Clerck, L., Peretz, A., Verbruggen, L., Vastesaeger, N., Noel, W., & De Keyser, F. (2008). Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population. Rheumatology (Print), 47, II39-II39. https://hdl.handle.net/2078.5/64967 (Original work published 2008)